Search
for
Sort by
Research 331–360 of 1000+
- Review of efficacy of baricitinib in the treatment of alopecia areata
- DataSheet1_Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention.PDF
- Reply to early onset effluvium secondary to COVID-19 and body-hair effluvium
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- The Economic Burden of Alopecia Areata: Evidence from a Survey in Norway and Sweden
- Androgenetic alopecia: An update
- Effectiveness of Tofacitinib in Pre-adolescent Alopecia Areata: A Retrospective Case Series and Literature Review
- <i>JAMA Dermatology—</i>The Year in Review, 2021
- Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment
- A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
- Human Placenta Extract (HPH) Suppresses Inflammatory Responses in TNF-α/IFN-γ-Stimulated HaCaT Cells and a DNCB Atopic Dermatitis (AD)-Like Mouse Model
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- Impacto del desequilibrio del microbioma del cuero cabelludo en la severidad de la alopecia areata, marcadores inflamatorios y cambios post-tratamiento
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Novel Quinazoline Derivative Induces Differentiation of Keratinocytes and Enhances Skin Barrier Functions against Th2 Cytokine-Mediated Signaling
- Emerging treatments in alopecia
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
- Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
- Ritlecitinib for the Management of Alopecia Areata: A Narrative Review of Real-World Evidence and Selected Post Hoc Analyses
- Baricitinib for the Treatment of Alopecia Areata
- Alopecia Areata
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up